An observational study in Graves Disease and COVID-19, sponsored by Qilu Hospital of Shandong University. Status unknown at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-05-28.
Sponsored by Qilu Hospital of Shandong University · Observational
The goal of this observational study is to learn about the correlation between COVID-19 and hyperthyroidism in Patients with hyperthyroidism complicated with COVID-19. The main questions it aims to answer are：
Longitudinal analysis of GD status was performed: Three follow-up time points were identified: before COVID-19, three months and one year after recovering from COVID-19 (the first follow-up visit, the second follow-up visit. Main collection items: Hyperthyroidism symptoms, signs, hyperthyroidism complications, psychological evaluation results, other complications，blood routine, liver and kidney function, thyroid function (FT3, FT4, TSH), thyroid-related antibodies, glucose and lipid metabolism (FBG, HbA1c, TC, TG, HDL-C, LDL-C), thyroid ultrasound and hyperthyroidism medication.Through this to understand the changes of hyperthyroidism in HT patients complicated with COVID-19 and the changes of anxiety and depression in hyperthyroidism patients before and after SARS-CoV-2 infection.And the effect of psychological intervention in GD patients after COVID-19.
156 studies on the registry are indexed under Graves Disease; 54 are open to participants now.
This study's planned enrollment of 120 is close to the median of 112 across 58 observational studies indexed under Graves Disease.
Browse Graves Disease studies →Qilu Hospital of Shandong University is the lead sponsor of 305 studies on the registry; 184 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The cases came from HT patients who were followed up in the outpatient department of general medicine of Qilu Hospital of Shandong University, and a total of 120 hyperthyroidism patients were enrolled, who are in the maintenance stage of HT treatment and have a history of COVID-19 in the past 3 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
COVID-19 is mild in hyperthyroidism patients with short course of disease.
Other: Thyroid metabolic index
The symptoms and immune level of COVD-19 in this group are in the middle level.
Other: Thyroid metabolic index
Theoretically, the symptoms and immune level of COVD-19 in this group are the worst.
Other: Thyroid metabolic index
The following indicators were collected from these patients: hyperthyroidism symptoms, signs, hyperthyroidism complications, psychological evaluation results, other complications，blood routine, liver and kidney function, thyroid function (FT3, FT4, TSH), thyroid-related antibodies, glucose and lipid metabolism (FBG, HbA1c, TC, TG, HDL-C, LDL-C), thyroid ultrasound and hyperthyroidism medication. Psychological evaluations (using the 7-item Generalized Anxiety Disorder Questionnaire, GAD-7, and the Patient Health Questionnaire 9, PHQ-9) and interventions.
Also known as: psychological evaluations, psychological interventions
Serum TSH were measured with chemiluminescence method.
TSH in µIU/mL
Time frame: Up to 9 months
Serum FT4 were measured with chemiluminescence method.
FT4 in pmmol/L
Time frame: Up to 9 months
Serum FT3were measured with chemiluminescence method.
FT3 in pmmol/L
Time frame: Up to 9 months
Serum TRAb were measured with chemiluminescence method.
TRAb in IU/L
Time frame: Up to 9 months
Serum TPO-Ab were measured with chemiluminescence method.
TPO-Ab in IU/ml
Time frame: Up to 9 months
Serum TTG-Ab were measured with chemiluminescence method.
TG-Ab in IU/ml
Time frame: Up to 9 months
Assess the changes of patients' psychological state with Generalized Anxiety Disorder-7 Items Scale（GAD-7)
Evaluation of anxiety state by GAD-7 scale. The lowest score of DAD-7 is 0, and the highest score is 21. The higher the score, the heavier the anxiety.
Time frame: Up to 9 months
Assess the changes of patients' psychological state with Patient Health Questionnaire-9（PHQ-9）
Evaluation of depression by PHQ-9 scale. The lowest score of PHQ-9 is 0, and the highest score is 27. The higher the score, the heavier the depression.
Time frame: Up to 9 months
Plan to share: Undecided
No publications or documents are linked to this record.
This study is status unknown, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Qilu Hospital of Shandong University →